Clinical trials: Unresectable Solid Neoplasm
Advanced Unresectable Solid Tumors
Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors
This is a first-in-human, open-label, dose escalation and expansion, 2-part study to determine the safety, tolerability, and maximum tolerated dose of Andes-1537 for Injection in patients with advanced unresectable solid tumors…
- Trial name
- NCT02508441
- Testing
- Andes-1537 for Injection
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Andes Biotechnologies
Metastatic or Locally Advanced Unresectable Solid Tumors
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
This is a Phase I, open-label study to determine the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and preliminary antitumor activity of MS201408-0005A as single agent (Part IA only) and in combination with…
- Trial name
- NCT03306420
- Testing
- M4112
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Recurrent Non-small Cell Lung Cancer, Recurrent Prostate Cancer
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
Phase I/II trial to study the effectiveness of combining GTI-2040 with docetaxel in treating patients who have recurrent, metastatic, or unresectable locally advanced non-small cell lung cancer, prostate cancer, or other solid…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Non-small Cell Lung Cancer
- Trial name
- NCT00074022
- Testing
- GTI-2040, docetaxel, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Liver Metastases
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
The primary objective of this phase IIb/III, prospective, randomized clinical trial is to compare the efficacy of irreversible electroporation (IRE) with stereotactic body radiotherapy (SBRT) in patients with perivascular or…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Unresectable Solid Tumor
- Trial name
- COLDFIRE-III (NCT06185556)
- Testing
- Irreversible electroporation, Stereotactic body radiotherapy
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Amsterdam UMC, location VUmc
Unspecified Adult Solid Tumor, Protocol Specific
Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004173
- Testing
- oxaliplatin, paclitaxel
- Where
- United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Advanced Malignant Tumor
QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors
In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with…
- Trial name
- NCT04326829
- Testing
- QL1604
- Where
- 2 sites in China
- Volunteers
- 86 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Recurrent Ovarian Carcinoma
Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors
This is a prospective, single-arm, single-center registry study to investigate 6-month progression-free survival with Dalpiciclib, a CDK4/6 kinase inhibitor, plus letrozole in patients with unresectable refractory or resistant…
- Trial name
- NCT06243185
- Testing
- Dalpiciclib plus letrozole
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fengzhi Feng
Solid Tumours
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab…
- Trial name
- IMFINZI-subQ (NCT07391670)
- Testing
- SC durvalumab + rHu, IV durvalumab, Tremelimumab
- Where
- 19 sites in Australia, Georgia and 3 more
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
This phase I trial studies the best dose and side effects of tazemetostat in treating patients with solid tumors or B-cell lymphomas with liver dysfunction that have spread to other places in the body or cannot be removed by…
- Conditions
- Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT03217253
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Tazemetostat
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma
- Trial name
- NCT07189195
- Testing
- TR-002
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of California, Davis
Unresectable or Metastatic Solid Tumors
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of…
- Trial name
- NCT03589651
- Testing
- Retifanlimab, Epacadostat, INCB050465
- Where
- 9 sites in United States
- Volunteers
- 83 people
- Sponsor
- Incyte Corporation
Solid Tumors
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
- Trial name
- NCT06963281
- Testing
- IBI3020
- Where
- 9 sites in United States, China
- Volunteers
- 285 people
- Sponsor
- Fortvita Biologics (USA)Inc.
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
This phase I/IIa trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma
- Trial name
- NCT02650986
- Testing
- Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Adult Solid Tumor, Breast Cancer
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. St. John's wort may interfere with the effectiveness of chemotherapy.
- Conditions
- Adult Solid Tumor, Breast Cancer, Head and Neck Cancer, Kidney and Urinary Cancer
- Trial name
- NCT00041171
- Testing
- Hypericum perforatum, docetaxel
- Sponsor
- Alliance for Clinical Trials in Oncology
Unspecified Adult Solid Tumor, Protocol Specific
17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
This phase I trial is studying the side effects and best dose of 17-AAG when given together with sorafenib in treating patients with unresectable or metastatic solid tumors.
- Trial name
- NCT00121264
- Testing
- sorafenib tosylate, tanespimycin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
1. Primary Objective: The primary endpoint to this study will be to document the toxicities, and reversibility of toxicities, of this regimen of hydralazine and valproic acid in patients with advanced, unresectable, previously…
- Trial name
- NCT00996060
- Testing
- Hydralazine and Valproic Acid: Cohort -1, Hydralazine and Valproic Acid: Cohort 0, Hydralazine and Valproic Acid: Cohort 1
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- New Mexico Cancer Research Alliance
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
This phase I trial tests the safety, side effects, and best dose of ZEN003694 when given together with abemaciclib in treating patients with NUT carcinoma, breast cancer or other solid tumors that have spread from where it first…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT05372640
- Testing
- Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
- Conditions
- Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive
- Trial name
- NCT06714617
- Testing
- BL-M17D1
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- SystImmune Inc.
Solid Tumors
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy dose-escalation and dose expansion study of RO7444973.The aim of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and…
- Trial name
- NCT05129280
- Testing
- RO7444973, Tocilizumab
- Where
- 10 sites in United States, Australia and 4 more
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche